Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Neurocrine Biosciences, Inc.
Positive phase I trial reported with orally active GnRH receptor antagonist
July 30th, 2003
Neurocrine Biosciences, Inc., (NBIX) announced positive results from the company's phase I clinical trial with its proprietary, orally active small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple dosing of NBI-42902 in healthy premenopausal women. Results demonstrated that NBI-42902 was safe and well-tolerated. Eighteen healthy premenopausal women participated in this randomized, double-blind, placebo-controlled, parallel-group, multiple-dose regimen study. The subjects were assigned to three groups of six with each subject receiving daily doses of...
Source: Biotech Week (2003-07-30)
|
